The Hepatitis C Virus (HCV) is one of the incredibly common modes of infections across the globe. Around 170 million people are being infected with the disease and the toughest challenge to eradicate HCV is when the cases are asymptomatic.
While researchers across the world are working hard for major progress in the diagnostic process, a latest study, led by the International Liver Congress in Paris, France has found something new to cure the disease.
According to the large-scale study, conducted in India, a decentralised care and the provision of free direct-acting antiviral agents (DAAs) can produce high rates of cure among people with hepatitis C virus (HCV) infection.
The latest findings, which were appeared on Fruday, validated the efficacy and safety of generic all-oral DAA regimens delivered using a decentralised algorithm-based public health model.
"We have shown in our study that it is possible to cure more than 90 per cent of individuals with HCV infection in a highly dispersed population using well-trained teams in government medical colleges and district hospitals, and widely available DAAs," said Professor Radha Krishan Dhiman from the Postgraduate Institute of Medical Education and Research in Chandigarh.
"We believe the Punjab Model could be applied to many different populations with the aim of eliminating HCV," Dhiman said.
The burden of HCV is particularly heavy in the Indian state of Punjab, owing to the high prevalence of risk factors such as unsafe medical practices - including unsafe medical injections, blood transfusions and dental procedures - and intravenous drug use.
Similar to other geographical regions in India, genotype 3 predominates in the state of Punjab.
The study assessed the feasibility of delivering decentralised HCV care via three government medical colleges and 22 district hospitals, and required the training of approximately 90 medical specialists, pharmacists and data managers.
A cost-effective treatment algorithm was developed using sofosbuvir-based regimens to treat all patients with HCV infection, with regimens selected based on the presence/absence of cirrhosis and HCV genotype.
A total of 29,371 patients (61.7 per cent male; mean age 42 years) were enrolled in one year, of which 19,646 patients completed treatment with a sustained virological response (SVR) at 12 weeks of 92.5 per cent.
Cure rates among individuals with cirrhosis (93.1 per cent) and without cirrhosis (92.4 per cent), and those with genotype 3 (92.6 per cent) and other genotypes (93.1 per cent), were similar.
"This study is an impressive example of how to upscale the treatment of hepatitis C, which is important to reduce hepatitis C-related complications, particularly the development of hepatocellular carcinoma," said Professor Markus Cornberg from the Hannover Medical School in Germany.
(With inputs from agencies)